Cardiovascular Toxicity Related to Cancer Treatment II

Dear Colleagues,

Due to the success of the first edition of the Special Issue “Cardiovascular Toxicity Related to Cancer Treatment ”(https://www.mdpi.com/journal/jcdd/special_issues/cardiovascular_toxicity), we have launched a second edition.

Cancer patients receiving chemotherapy have an increased risk of developing cardiovascular complications, and the risk is even greater if there is a known history of heart disease. Among the serious complications that have been reported are arrhythmias, myocardial necrosis causing a dilated cardiomyopathy, vasospasm or vaso-occlusion resulting in angina or myocardial infarction and pericardial disease. A wide range of chemotherapy agents have been associated with cardiotoxicity, for which the anthracyclines and related compounds (which may have been administered in childhood) are the most frequently implicated agents. Optimum preventive and therapeutic management of cardiotoxicity requires a multidisciplinary approach with close collaboration between the treating oncologist and cardiologist. Novel diagnostic imaging modalities and biomarkers have an established role in screening, diagnosis and follow-up of cardiotoxicity. Limited data from small trials are available to guide prevention and management of cardiotoxicity. In this focused issue, we sought to review recent advances in the field of Cardio-Oncology and specifically focus on the role of prevention, newer agents that may cause myocardial damage and also strategies and challenges to launching and sustaining a Cardio-Oncology clinic. Experts in the field of Cardio-Oncology are invited to critically review the literature on the following topics:

1) Cardio-protection to prevent the cardiotoxic effects of chemotherapeutic agents: whom to treat and how?

2) Cardiotoxicity of non-anthracycline cancer chemotherapy agents: focus on immunotherapy

3) Practical approaches to build and sustain a Cardio-Oncology program

Dr. Alexandros Briasoulis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Dr. Alexandros Briasoulis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cardiotoxicity
• anthracycline induced cardiomyopathy
• global longitudinal strain
• cardio-oncology
• immunotherapy induced myocarditis